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LETTERS TO THE EDITOR 
Cardioprotection by adenosine: Is it a question of 
effective dose, timing, or the target compartment? 
To the Editor: 
We read with great interest the excellent study by 
Randhawa, Lasley, and Mentzer, ~ which tested the car- 
dioprotective ffect of preischemic (pretreatment) intra- 
coronary adenosine versus postischemic (i.e., onset of 
reperfusion) intracoronary adenosine administration i a 
porcine model of contractile "stunning." This study was 
based on the authors' hypotheses that (1) the cardiopro- 
tective effects of adenosine were mediated principally via 
the A s receptor subtype located on the myocyte and (2) 
adenosine-induced cardioprotection required an accumu- 
lation of the purine in the interstitial fluid compartment. 
Adenosine was administered by intracoronary infusion 
either before coronary occlusion (either 5 or 50/xg/kg per 
minute for 10 minutes) or immediately on the onset of 
reperfusion (50 txg/kg per minute for 30 minutes). The 
investigators found that pretreatment adenosine at both 
low and high doses significantly attenuated postischemic 
contractile stunning in the ischemic-reperfused area, al- 
though accumulation of adenosine in the interstitial fluid 
compartment (microdialysis) was significant only in the 
group receiving 50/~g/kg per minute. In contrast, adeno- 
sine administered at reperfusion had no salutary effect 
and failed to increase interstitial fluid adenosine. The 
authors concluded that (1) intracoronary adenosine is 
cardioprotective optimally when given before ischemia, 
(2) adenosine levels in the interstitial compartment must 
be augmented to exert this protection, and (3) the mech- 
anism underlying this cardioprotection is likely related to 
an interaction of adenosine with its A~ receptor subtype 
on the myocyte. A mechanism related to A2 receptor 
activation was thought not to be involved. 
The requirement for adenosine accumulation i  the 
interstitial compartment has recently come under vigor- 
ous investigation. Van Wylen 2 has shown that the critical 
concentration of intravascular denosine needed to over- 
come the endothelial "sink" or barrier and augment 
interstitial adenosine concentrations is approximately 5 to 
10 /~g/kg per minute, which is close to the lowest dose 
used in the study under discussion. The failure of the 5 
~g/kg per minute dose to augment interstitial fluid aden- 
osine above preinfusion levels may be related to the 
inability of adenosine to traverse this barrier. However, 
the enhanced recovery of contractile function in this 
low-dose group in the absence of augmented interstitial 
levels is inconsistent with a requirement for interstitial 
accumulation. As recently demonstrated by Lasley and 
colleagues, 3 cardioprotection cannot be explained by sim- 
ple augmentation f interstitial adenosine concentrations. 
In addition to the interstitial (myocyte) compartment, a 
major and alternative target for adenosine is the vascular 
compartment. Adenosine, via activation of A2 receptors, 
has potent inhibitory effects on neutrophils, resulting in 
attenuated production of superoxide anions, inhibition of 
202  
adherence to the vascular endothelium (purportedly a
major initiating step in the inflammatory cascade involved 
in reperfusion injury), and a reduction in neutrophil- 
mediated endothelial damage. The importance of the 
intravascular space as a site for adenosine-mediated car- 
dioprotection, independent of interstitial actions, has re- 
cently been shown by Todd and associates. 4 They showed 
that macromolecular denosine, confined to the intravas- 
cular compartment, reduced infarct size in a rabbit model 
of myocardial reperfusion injury. Therefore the intravas- 
cular compartment may be a significant site of action of 
adenosine, in addition to the myocyte interstitial compart- 
ment. 
When does adenosine xert cardioprotection in the two 
compartments mentioned? Randhawa, Lasley, and 
Mentzer 1found that a beneficial effect of adenosine was 
exerted in their nonlethal model only when adenosine was 
administered as a pretreatment, and not when infused 
during reperfusion alone. However, the literature is rich 
with studies in which adenosine (both exogenous and 
endogenous) exerts cardioprotection during the reperfu- 
sion phase. In addition, activation of the A2 receptor 
specifically, rather than the A1 receptor, was found in a 
number of studies to be primarily involved in protecting 
the heart from ischemic-reperfusion injury. Zhao and 
associates s found that endogenous adenosine released 
during ischemia reduced infarct size predominantly b  an 
A2-mediated effect, that is, activation of adenosine A 2 
receptors. This finding has been extended to exogenous 
adenosine administered only during reperfusion. The 
cardioprotection byA 2 receptor activation is likely due to 
inhibition of neutrophil activities involved in the patho- 
genesis of reperfusion injury, as discussed earlier. There- 
fore A2-mediated effects exerted during reperfusion, in 
addition to Al-mediated mechanisms active during reper- 
fusion, are key factors in the overall cardioprotection 
exhibited by adenosine. 
The apparent questions raised by the study of 
Randhawa, Lasley, and Mentzer ~ regarding the optimal 
timing of adenosine administration and the receptor 
mechanisms involved may be related to the intended 
target of therapy and the compartment in which that 
target resides. A pretreatment administration of adeno- 
sine, as used by Randhawa, Lasley, and Mentzer, 1 both 
reduces infarct size and enhances functional recovery by 
predominantly Al-mediated mechanisms, possibly by ac- 
tivation of adenosine triphosphate-sensitive potassium 
channels. On the other hand, adenosine or analogs ad- 
ministered exclusively at the time of reperfusion signifi- 
cantly reduce infarct size (lethal injury), probably by 
inhibiting neutrophil by A 2 receptor-mediated ffects 
through activation of A 2 receptors. However, neutrophils 
have not been clearly implicated in the pathogenesis of
postischemic contractile stunning (nonlethal injury) be- 
cause stunning occurs in neutrophil-free models. There- 
fore targeting neutrophil activation during the reperfusion 
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phase will likely not alter postischemic stunning, although 
other mechanisms of injury would be engaged. This 
explanation is consistent with the data presented in the 
study by Randhawa, Lasley, and Mentzer a and is consis- 
tent with other studies related to the cardioprotective 
mechanisms of adenosine. 
The optimal timing of adenosine administration may 
span all three windows of protection: before treatment, 
during the ischemic event, and during reperfusion. In 
cardiac surgery, these three windows of protection are 
open. First, adenosine can be given as a pretreatment 
before the operation. Second, adenosine may be included 
as an adjunct o either crystalloid or blood cardioplegia, 6 
in which case it is administered uring surgical "pro- 
tected" ischemia. Third, adenosine may be administered 
after aortic unclamping and reperfusion. Which "window" 
of administration is most optimal, what dose is optimal, 
which receptors and effector systems are targets of aden- 
osine, and in which compartment(s) protective ffects are 
exerted in the surgical setting are questions that will keep 
young basic scientists and physician-investigators at the 
bench for some time. 
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Reply to the Editor: 
We thank Drs. Vinten-Johansen and Hammon for their 
interest in our work entitled "Salutary Effects of Exoge- 
nous Adenosine Administration on In Vivo Myocardial 
Stunning. ''1 We reported that adenosine's cardioprotec- 
tive effects were related to the preischemic elevation of 
adenosine in interstitial fluid and subsequent activation of 
adenosine A1 receptors located on the cardiac myocytes. 
We also concluded that denosine must be administered 
before ischemia to attenuate stunning, because postisch- 
emic infusion of adenosine only transiently improved 
systolic wall thickening. 
As pointed out by Vinten-Johansen and Hammon, in 
one protocol in this study we observed attenuation of 
stunning with an adenosine pretreatment dose (5 /xg/kg 
per minute) that did not elevate preischemic dialysate 
adenosine concentrations. Although we acknowledged 
that the cardioprotective effect of this dose could have 
occurred independent of increased interstitial f uid aden- 
osine, we concluded that the lack of increase in dialysate 
adenosine may have been due to the limitations of the 
dialysis technique. This technique provides only an esti- 
mate of interstitial f uid metabolites and is dependent on 
blood flow. In subsequent s udies in the pig (unpublished 
data) we observed that the same intracoronary adenosine 
infusion (5/xg/kg per minute) increased coronary venous 
adenosine fivefold (from 0.31 + 0.09 /zmol/L to 1.51 + 
0.32 p~mol/L). We detected a much smaller increase in 
dialysate adenosine--from 0.55 _ 0.05/xmol/L to 0.71 --- 
0.11 txmol/L. We thus agree with Van Wylen 2 that the 
threshold intracoronary adenosine dose for overcoming 
the coronary endothelial barrier is approximately 5/xg/kg 
per minute. 
Because both doses of adenosine undoubtedly in- 
creased plasma adenosine levels, adenosine A2 receptors 
were presumably activated. However, it is unlikely that the 
cardioprotective effects of adenosine pretreatment are 
related to preischemic activation of adenosine Ae recep- 
tors. This hypothesis i based on the results of numerous 
studies in which adenosine A 1 and A2 receptor agonists 
and adenosine receptor antagonists were used. The pre- 
ischemic activation of adenosine A 1 receptors appears to 
be critical for the cardioprotective effects of adenosine 
against both reversible and irreversible injury. In our 
recent study in a model of irreversible injury, we 3 ob- 
served that a transient intravenous adenosine infusion 
(i.e., adenosine preconditioning) briefly increased preisch- 
emic levels of myocardial dialysate adenosine and reduced 
infarct size. The adenosine preconditioning did not, how- 
ever, alter dialysate concentrations during the prolonged 
occlusion. These results are consistent with our working 
hypothesis that the cardioprotective effects of adenosine 
pretreatment are mediated by the preischemic activation 
of adenosine A1 receptors, irrespective of ischemic inter- 
stitial fluid adenosine levels. 
Although the cardioprotective effects of adenosine pre- 
treatment in models of stunning and infarction are 
thought o be mediated by adenosine Aa receptor activa- 
tion, we agree with Drs. Vinten-Johansen and Hammon 
that adenosine exerts beneficial effects during reperfusion 
of the irreversibly injured heart. As suggested by several 
studies from Dr. Vinten-Johansen's laboratory, these ef- 
fects appear to be mediated by activation of adenosine A 2 
receptors located on endothelial cells and neutrophils. In 
fact, there is evidence that, in contrast o the beneficial 
